CANDEL THERAPEUTICS, INC. Deferred Costs, Noncurrent
CANDEL THERAPEUTICS, INC. (CADL) had Deferred Costs, Noncurrent of $0 as of 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Balance Sheet › Assets, Noncurrent
us-gaap:DeferredCosts · last filed 2021-11-12
- 2021-09-30: Deferred Costs, Noncurrent $0.00.
- 2021-06-30: Deferred Costs, Noncurrent $1.30M.
- 2020-12-31: Deferred Costs, Noncurrent $83.00K.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 |
| 2021-06-30 | $1.30M 10-Q · filed 2021-09-08 |
| 2020-12-31 | $83.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |